Adaptimmune Therapeutics plc 473A.F Stock
Adaptimmune Therapeutics plc Price Chart
Adaptimmune Therapeutics plc 473A.F Financial and Trading Overview
| Adaptimmune Therapeutics plc stock price | 1.07 EUR |
| Previous Close | 0.94 EUR |
| Open | 0.91 EUR |
| Bid | 0.91 EUR x 90000 |
| Ask | 0.94 EUR x 90000 |
| Day's Range | 0.91 - 0.91 EUR |
| 52 Week Range | 0.91 - 2.52 EUR |
| Volume | 1 EUR |
| Avg. Volume | 12 EUR |
| Market Cap | 213.43M EUR |
| Beta (5Y Monthly) | 2.262676 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.83 EUR |
473A.F Valuation Measures
| Enterprise Value | 13.04M EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.91 |
| PEG Ratio (5 yr expected) | -5.04 |
| Price/Sales (ttm) | 2.9986634 |
| Price/Book (mrq) | 1.7984191 |
| Enterprise Value/Revenue | 0.183 |
| Enterprise Value/EBITDA | -0.128 |
Trading Information
Adaptimmune Therapeutics plc Stock Price History
| Beta (5Y Monthly) | 2.262676 |
| 52-Week Change | -38.33% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.52 EUR |
| 52 Week Low | 0.91 EUR |
| 50-Day Moving Average | 1.12 EUR |
| 200-Day Moving Average | 1.44 EUR |
473A.F Share Statistics
| Avg. Volume (3 month) | 12 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 225.05M |
| Float | 96.99M |
| Short Ratio | N/A |
| % Held by Insiders | 0.31% |
| % Held by Institutions | 70.02% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -160.38% |
| Operating Margin (ttm) | -152.20% |
| Gross Margin | -63.71% |
| EBITDA Margin | -143.31% |
Management Effectiveness
| Return on Assets (ttm) | -19.12% |
| Return on Equity (ttm) | -92.42% |
Income Statement
| Revenue (ttm) | 71.17M EUR |
| Revenue Per Share (ttm) | 0.44 EUR |
| Quarterly Revenue Growth (yoy) | 1231.50% |
| Gross Profit (ttm) | -100578000 EUR |
| EBITDA | -102003000 EUR |
| Net Income Avi to Common (ttm) | -114155000 EUR |
| Diluted EPS (ttm) | -0.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 165.55M EUR |
| Total Cash Per Share (mrq) | 1 EUR |
| Total Debt (mrq) | 22.83M EUR |
| Total Debt/Equity (mrq) | 27.22 EUR |
| Current Ratio (mrq) | 3.359 |
| Book Value Per Share (mrq) | 0.506 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -124651000 EUR |
| Levered Free Cash Flow (ttm) | -67776000 EUR |
Profile of Adaptimmune Therapeutics plc
| Country | Germany |
| State | N/A |
| City | Abingdon |
| Address | 60 Jubilee Avenue |
| ZIP | OX14 4RX |
| Phone | 44 12 3543 0000 |
| Website | https://www.adaptimmune.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 534 |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Q&A For Adaptimmune Therapeutics plc Stock
What is a current 473A.F stock price?
Adaptimmune Therapeutics plc 473A.F stock price today per share is 1.07 EUR.
How to purchase Adaptimmune Therapeutics plc stock?
You can buy 473A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Adaptimmune Therapeutics plc?
The stock symbol or ticker of Adaptimmune Therapeutics plc is 473A.F.
Which industry does the Adaptimmune Therapeutics plc company belong to?
The Adaptimmune Therapeutics plc industry is Biotechnology.
How many shares does Adaptimmune Therapeutics plc have in circulation?
The max supply of Adaptimmune Therapeutics plc shares is 255.56M.
What is Adaptimmune Therapeutics plc Price to Earnings Ratio (PE Ratio)?
Adaptimmune Therapeutics plc PE Ratio is now.
What was Adaptimmune Therapeutics plc earnings per share over the trailing 12 months (TTM)?
Adaptimmune Therapeutics plc EPS is -0.5 EUR over the trailing 12 months.
Which sector does the Adaptimmune Therapeutics plc company belong to?
The Adaptimmune Therapeutics plc sector is Healthcare.